Clinical Trial Update: A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effects of GSK573719 alone and in combination with vilanterol (VI) in adults with moderate hepatic impairment and matched healthy v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719
• Vilanterol (vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED